SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Merrimack Pharmaceuticals, Inc. (MACK) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 51/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — MACK
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.08
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2014 |
$-7.98 |
$102.76M |
$-83.29M |
-81.1% |
| 2015 |
$-13.29 |
$89.26M |
$-147.96M |
-165.8% |
| 2016 |
$-12.11 |
$144.27M |
$-151.74M |
-105.2% |
| 2017 |
$35.67 |
$0.00 |
$472.03M |
- |
| 2018 |
$-3.04 |
$0.00 |
$-40.51M |
- |
| 2019 |
$-1.59 |
$0.00 |
$-21.27M |
- |
| 2020 |
$-0.23 |
$0.00 |
$-3.03M |
- |
| 2021 |
$-0.18 |
$0.00 |
$-2.46M |
- |
| 2022 |
$-0.11 |
$0.00 |
$-1.54M |
- |
| 2023 |
$-0.08 |
$0.00 |
$-1.18M |
- |
